Evidence map›Paper›PMID 31803652›Full record

ArticleJournal of family medicine and primary care2019

Pattern of antinuclear antibody and antiextractable nuclear antigen antibody test requisitions in Riyadh.

Najla Ali Alghabban, Zahid Shakoor

Open access · goldAbstract read
In one paragraph

Article in Journal of family medicine and primary care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Najla Ali AlghabbanDepartment of Family Medicine, King Khalid Medical City, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Zahid ShakoorDepartment of Pathology, King Khalid Medical City, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia.
King Saud Medical City · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInternational guidelines for screening of systemic autoimmune rheumatic diseases (SARD) recommend antinuclear antibody (ANA) test as the first level test and antiextractable antigen (anti-ENA) along with anti-double-stranded DNA (anti-dsDNA) as second line tests following a reactive ANA test. This study was performed to assess adherence to international guidelines for investigation of SARD and to compare the requesting pattern of ANA and second level tests between rheumatology and nonrheumatology physicians in Riyadh. METHODOLOGY: This retrospective cross-sectional study comprising of 300 first time requests for investigation of SARD was performed in the immunology unit at King Khalid University Hospital (KKUH). Data were collected between April and May 2018. Information regarding the requesting physicians' specialty and the first time requested tests (ANA, anti-dsDNA, and anti-ENA) were extracted from the electronic medical records. Reasons for requisition of tests were also recorded.

resultsOf the total requests, 159 (53%) requests included ANA as a single first level test, whereas the rest of the requests (

conclusionANA and second level tests requests by physicians particularly among rheumatologists lacked compliance to international guidelines. The current study strongly suggests the need for strict compliance to international guidelines for screening of systemic autoimmune disorders among physicians.

Indexed as

ANA testfirst level test in SARDsSARDssecond level test in SARD

Identifiers

PMID31803652
PMCPMC6881934
OpenAlexW2985609711

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.